CARGO TherapeuticsCRGX
Market Cap: 819M
About: Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.
Employees: 123
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
250% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 6
200% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 10
44% more funds holding
Funds holding: 45 [Q4 2023] → 65 (+20) [Q1 2024]
7.57% more ownership
Funds ownership: 84.88% [Q4 2023] → 92.45% (+7.57%) [Q1 2024]
0% more capital invested
Capital invested by funds: $809M [Q4 2023] → $812M (+$2.77M) [Q1 2024]
33% less funds holding in top 10
Funds holding in top 10: 3 [Q4 2023] → 2 (-1) [Q1 2024]
Research analyst outlook
5 Wall Street Analysts provided 1 year price forecasts over the past 6 months
5 analyst ratings
HC Wainwright & Co. Robert Burns | 85%upside $33 | Buy Initiated | 22 Jul 2024 |
Chardan Capital Geulah Livshits | 57%upside $28 | Buy Initiated | 8 Jul 2024 |
Piper Sandler Biren Amin | 107%upside $37 | Overweight Initiated | 27 Jun 2024 |
Truist Securities Asthika Goonewardene | 79%upside $32 | Buy Reiterated | 16 May 2024 |
Jefferies Michael Yee | 79%upside $32 | Buy Maintained | 22 Mar 2024 |